Fight CRC Clinical Trial Finder
| NCT ID | Title | 阶段 | Date Added | 地点 | Prior IO Allowed | CRC-directed | Status | 药物 | 标签 |
|---|---|---|---|---|---|---|---|---|---|
| NCT ID NCT06253520 |
TitleAutologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer | 阶段
第 1 阶段
|
Date Added 2024-02-12 |
地点
Maryland, United States
|
Prior IO Allowed 是 |
CRC-directed 是 |
Status
招聘
|
药物
Aldesleukin, Cyclophosphamide, Fludarabine |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT06043713 |
Title表达高亲和性 KRASG12V 突变特异性 T 细胞受体的自体 CD8+ 和 CD4+ 转基因 T 细胞（FH-A11KRASG12V-TCR）用于治疗 KRAS G12V 突变的转移性胰腺癌、结直肠癌和非小细胞肺癌患者 | 阶段
第 1 阶段
|
Date Added 2023-09-21 |
地点
Washington, United States
|
Prior IO Allowed 是 |
CRC-directed 没有 |
Status
活跃，非招募
|
药物
Bendamustine, Cyclophosphamide, Fludarabine |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT03638206 |
Title治疗恶性肿瘤的自体 CAR-T/TCR-T 细胞免疫疗法 | 阶段
第 1 阶段/第 2 阶段
|
Date Added 2018-08-20 |
地点
中国
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物
CAR-T cell immunotherapy |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05141474 |
Title评估体外下一代新抗原选择的肿瘤浸润淋巴细胞（TIL）疗法在晚期上皮肿瘤和免疫检查点阻断剂（ICB）耐受性实体瘤中的安全性和耐受性 | 阶段
早期阶段 1
|
Date Added 2021-12-02 |
地点
西班牙
|
Prior IO Allowed 是 |
CRC-directed 没有 |
Status
招聘
|
药物
Interleukin-2, NEXTGEN-TIL, Non-myeloablative Lymphodepletion (NMA-LD) Regimen |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT03832855 |
Title评估 pING-hHER3FL 的免疫原性 | 阶段
第 1 阶段
|
Date Added 2019-02-06 |
地点
North Carolina, United States
|
Prior IO Allowed 是 |
CRC-directed 没有 |
Status
招聘
|
药物
pING-hHER3FL |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT03829462 |
Title评估转移性结直肠癌患者服用瑞戈非尼-伊立替康复方制剂与单用瑞戈非尼的效果 | 阶段
第三阶段
|
Date Added 2019-02-04 |
地点
法国
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
Irinotecan, Regorafenib |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05464030 |
TitleAnti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01) | 阶段
第 1 阶段
|
Date Added 2022-07-19 |
地点
California, United States
Rhode Island, United States Texas, United States 加拿大 日本 大韩民国 西班牙 |
Prior IO Allowed 是 |
CRC-directed 是 |
Status
招聘
|
药物
M9140 |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT04432857 |
TitleAN0025 and Pembrolizumab Combination in Advanced Solid Tumors | 阶段
第 1 阶段
|
Date Added 2020-06-16 |
地点
Missouri, United States
Texas, United States Utah, United States Virginia, United States 法国 |
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
AN0025, Pembrolizumab |
标签
MSS/ MMRp
|
| NCT ID NCT04660812 |
TitleAn Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer. | 阶段
Phase 1, Phase 2
|
Date Added 2020-12-09 |
地点
Alabama, United States
Arizona, United States California, United States Connecticut, United States District of Columbia, United States Georgia, United States Louisiana, United States Maryland, United States Missouri, United States Nevada, United States New York, United States Pennsylvania, United States South Carolina, United States Tennessee, United States Texas, United States Wisconsin, United States 法国 意大利 大韩民国 西班牙 英国 |
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
AB680, Bevacizumab, Etrumadenant, mFOLFOX-6 regimen, Regorafenib, Zimberelimab |
标签
MSS/ MMRp
|
| NCT ID NCT03994601 |
TitleBMS-986288单独或与Nivolumab联合治疗晚期实体瘤的免疫疗法研究 | 阶段
第 1 阶段
|
Date Added 2019-06-21 |
地点
California, United States
Colorado, United States Maryland, United States Missouri, United States New Jersey, United States 阿根廷 加拿大 智利 法国 意大利 西班牙 |
Prior IO Allowed 是 |
CRC-directed 没有 |
Status
活跃，非招募
|
药物
BMS-986288, Nivolumab, Opdivo |
标签
MSI-H/ MMRd, MSS/ MMRp
|
